HBA1
Hemoglobin subunit alpha
As of the edition of 20 October 2026, HBA1 (hemoglobin subunit alpha, UniProt P69905) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P69905
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 357
- Disease areas
- Blood and lymph; Inherited and neonatal; Cancer; Lungs and airways; Nervous system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 34
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Voxelotor | Withdrawn from market | Phase 4 | Ends 2035 |
| Efaproxiral | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Zydus Worldwide DMCC | Route A |
The other 0 companies at HBA1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at HBA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.